SOUTH KOREA — Novartis’ generic drugs division, Sandoz, has forged a strategic collaboration with Samsung Bioepis to develop a biosimilar version of Johnson & Johnson’s widely-used anti-inflammatory drug, Stelara. Stelara…
Read MoreTag: Samsung Bioepis
Drugmakers introduce cheaper alternatives to Humira, a blockbuster arthritis drug
USA — Drug manufacturers Organon and Samsung Bioepis have announced the launch of a lower-cost biosimilar version of AbbVie’s blockbuster arthritis drug, Humira. In addition, two other drug manufacturers have…
Read MoreSamsung Biologics shells US$2.3 bln to complete acquisition of Samsung Bioepis
SOUTH KOREA – Samsung Biologics has completed the US$2.3 billion acquisition of Biogen’s stake in the Samsung Bioepis joint venture. Samsung Biologics signed a stake acquisition agreement in January of…
Read More